During Donald Trump’s presidency, India is prepared for potential disruptions to its pharmaceutical industry, where the British industry accounts for about a third of imports.
Bioplus Life Sciences, a Bangalore-based pharmaceutical firm, is one of the companies that produces generic medications and exports its goods to the United States.  ,
It accounts for a sizable portion of the company’s yearly revenue of almost US$ 1 million. It is a critical component of its business. However, the agency’s president Sundeep Aurora is no discounting that its earnings could be impacted by Trump’s taxes.
“You’re going to have a 10 to 20 per cent value increase, probably into the US. And truly, there’s going to be a restructuring of supply stores around the world”, he said.
According to the Indian Pharmaceutical Alliance, made-in-India common medications accounted for nearly half of all prescription medications in the US in 2022. In the prior fiscal year, they accounted for about US$ 8.7 billion in biotech exports from India to the US.
Trump, who will take the oath of office on Monday ( Jan 20 ), has pledged to impose reciprocal tariffs in response to India’s high import tariffs on some American goods.
American drug manufacturers are also concerned about Trump’s America First initiative, which could result in a rise in local production and a decline in American export demand.